M17-05: MAGE-A3 vaccine
نویسندگان
چکیده
منابع مشابه
Construction, expression and purification of recombinant HBcAg-MAGE-A3 therapeutic cancer vaccine
Objective: To construct and identify recombinant expression of a therapeutic tumor vaccine with HBcAg as a vector. Methods: PCR primers were designed according to the gene sequences of restriction enzyme sites of recombinant pKK233.2-hepatitis B core antigen (HBcAg) and melanoma-associated antigen 3 (MAGE-A3: 112120aa). The target fragment of MAGE-A3 was synthesized and cloned to pKK233.2-HBcAg...
متن کاملMAGE-A3 with cell-penetrating domain as an efficient therapeutic cancer vaccine.
IMPORTANCE In conjunction with chemotherapy, immunotherapy with dendritic cells (DCs) may eliminate minimal disease burden by generating cytotoxic T lymphocytes. Enhanced cytosolic bioavailability of tumor-specific antigens improves access to human leukocyte antigen (HLA) class I molecules for more efficient cytotoxic T lymphocyte generation. Various cell-penetrating domains (CPDs) are known to...
متن کاملExpression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer
Melanoma-associated antigen (MAGE)-A3 and MAGE-C2 are antigens encoded by cancer-germline genes, and have been recognized as potential prognostic biomarkers and attractive targets for immunotherapy in multiple types of cancer. The present study aimed to analyze the clinicopathological significance of MAGE-A3/C2 expression in non-small cell lung cancer (NSCLC). The association between MAGE-A3/C2...
متن کاملCancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells.
BACKGROUND Multiple myeloma is a life-threatening disease and despite the introduction of stem cell transplantation and novel agents such as thalidomide, lenalidomide, and bortezomib most patients will relapse and develop chemoresistant disease. Therefore, alternative therapeutic modes for myeloma are needed and cancer-testis antigens such as MAGE-C1/CT7 and MAGE-A3 have been suggested to repre...
متن کاملMAGE-A3-specific anticancer immunotherapy in the clinical practice
Antigen-specific immunotherapy may offer a unique approach to fight cancer. We have demonstrated that specific immunotherapeutic regimens involving recombinant melanoma antigen family A3 (MAGE-A3) and different immunostimulants exert clinical anticancer activity. In particular, the combination of recombinant MAGE-A3 and AS15, a multicomponent immunostimulant, was found to elicit robust antigen-...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2007
ISSN: 1556-0864
DOI: 10.1097/01.jto.0000282979.11489.9c